Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 5
Submit an article Journal homepage
410
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma

Swetha KambhampatiDepartment of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-4783-2643
ORCID Icon,
Derek GalliganDepartment of Medicine, Division of Hematology and Oncology, Oregon Health Sciences and University, Portland, OR, USA;
,
Chiung-Yu HuangDepartment of Epidemiology and Biostatistics, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA
,
Sandy WongDepartment of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA;
,
Jeffrey WolfDepartment of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA;
,
Thomas MartinDepartment of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA;
&
Nina ShahDepartment of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA;
show all
Pages 1211-1219 | Received 16 Oct 2019, Accepted 16 Dec 2019, Published online: 11 Jan 2020

References

  • Howlader NNA, Krapcho M, Miller D, et al. SEER Cancer Statistics Review. Bethesda (MD): National Cancer Institute; 1975–2013.
  • Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346–1348.
  • Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088–2096.
  • Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
  • Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018;124(20):4032–4043.
  • Laubach JP, Voorhees PM, Hassoun H, et al. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014;7(1):97–111.
  • Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63.
  • Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99(6):1885–1893.
  • Wuilleme-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19:1248–1252.
  • Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
  • DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
  • Wei AH, Strickland SA, Jr., Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. JCO. 2019;37(15):1277–1284.
  • Touzeau C, Maciag P, Amiot M, et al. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia. 2018;32(9):1899–1907.
  • Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210–212.
  • Gupta VA, Newman S, Bahlis NJ, et al. B-cell markers predict response to venetoclax in multiple myeloma. Blood. 2016;128(22):2108–2108.
  • Morales AA, Kurtoglu M, Matulis SM, et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells. Blood. 2011;118(5):1329–1339.
  • Punnoose EA, Leverson JD, Peale F, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15(5):1132–1144.
  • Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–2409.
  • Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–2400.
  • Costa LJ, Stadtmauer EA, Morgan GJ, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. JCO. 2018;36(15):8004–8004.
  • Kumar SHS, Cavo M, et al. A phase 3 study of venetoclax or placebo in combination with n combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Paper presented at: 2019 European Hematology Association Congress; 2019 June 13–16; Amsterdam, The Netherlands.
  • Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126(7):921–922.
  • Iyer PC, Cabanillas ME, Waguespack SG, et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018;28(10):1243–1251.
  • Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
  • Touzeau C, Le Gouill S, Mahe B, et al. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica. 2017;102(3):e112–e114.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.